Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CHEK | US
1.00
0.70%
Healthcare
Diagnostics & Research
31/03/2024
17/04/2026
143.00
142.00
143.00
141.00
Check-Cap Ltd. a clinical stage medical diagnostics company engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap an X-ray scanning capsule for detection of suspected polyps; C-Scan Track a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software a client/server-based application that enables procedure data download from the C-Scan Track data analysis and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya Israel.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
24.7%1 month
22.9%3 months
28219.1%6 months
29624.0%-
-
0.37
-
-
0.74
-
-
-17.65M
836.44M
836.44M
-
-
-
-
-54.06
0.73
0.23
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
15.00
Range1M
15.00
Range3M
169.55
Rel. volume
0.73
Price X volume
101.23M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Quidel Corporation | QDEL | Diagnostics & Research | 12.71 | 854.56M | 0.20% | n/a | 87.31% |
| Atossa Genetics Inc | ATOS | Diagnostics & Research | 5.83 | 733.16M | 1.04% | n/a | 0.00% |
| CASTLE BIOSCIENCES INC | CSTL | Diagnostics & Research | 25.05 | 694.81M | 2.00% | n/a | 5.94% |
| Fulgent Genetics Inc | FLGT | Diagnostics & Research | 16.26 | 492.62M | 0.81% | n/a | 1.18% |
| Varex Imaging Corporation | VREX | Diagnostics & Research | 12.01 | 490.74M | 3.53% | 16.69 | 80.92% |
| Myriad Genetics Inc | MYGN | Diagnostics & Research | 5.08 | 461.37M | 1.60% | n/a | 0.00% |
| Pacific Biosciences of California Inc | PACB | Diagnostics & Research | 1.69 | 460.57M | 3.68% | n/a | 187.73% |
| Personalis Inc | PSNL | Diagnostics & Research | 6.73 | 443.75M | 1.05% | n/a | 41.56% |
| Palatin Technologies Inc | PTN | Diagnostics & Research | 22.5 | 439.83M | 7.66% | n/a | -382.57% |
| National Research Corporation | NRC | Diagnostics & Research | 18.03 | 430.40M | 2.33% | 16.76 | 105.03% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.54 | 805.08M | 5.73% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.34 | 732.76M | 5.14% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.37 | 724.04M | 5.53% | 42.05 | 64.69% |
| HUYA Inc | HUYA | Media - Diversified | 3.18 | 719.86M | -0.62% | n/a | 0.00% |
| AMC Entertainment Holdings Inc | AMC | Media - Diversified | 1.86 | 672.12M | 15.53% | n/a | -511.14% |
| The Marcus Corporation | MCS | Media - Diversified | 19.82 | 637.68M | 5.99% | n/a | 83.32% |
| Ennis Inc | EBF | Building Products & Equipment | 21.67 | 563.50M | 1.69% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.54 | 530.55M | 7.32% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.4 | 388.61M | 6.32% | 34.27 | 26.82% |
| AMC Networks Inc | AMCX | Media - Diversified | 8.77 | 386.74M | 6.56% | 6.32 | 236.34% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.74 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 40.09 | - |
| Price to Book | 0.37 | 77.50 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 28,219.10 | - | Riskier |
| Debt to Equity | - | -14.36 | - |
| Debt to Assets | - | 0.34 | - |
| Market Cap | 836.44M | - | Emerging |